体外培养和冷冻保存对微囊化细胞生长和内皮抑素表达的影响

微囊化基因工程细胞移植治疗肿瘤是一种新兴的肿瘤治疗方法,如果将此技术应用到临床研究,就需要制备大量的细胞活性良好、重组蛋白表达量高的生物微胶囊。体外培养和冷冻保存是生物微胶囊制备过程中两个重要的环节,因此需要考察体外培养和冷冻保存对微囊化重组基因细胞生长和蛋白表达的影响。以重组CHO细胞为模型,考察了体外培养时间和冷冻保存对微囊化细胞在动物体内生长和内皮抑素表达的影响及体外培养时间对微囊化细胞冷冻保存的影响。结果表明:体外培养时间对微囊化细胞在动物体内生长、内皮抑素表达和微囊稳定性具有较大的影响,体外不培养和培养4d的微囊化细胞在小鼠腹腔内生长良好、内皮抑素表达量高,并且微囊稳定性好,而体外培养8d的微囊化细胞在移植后的第26天破裂。体外培养时间对微囊化细胞冷冻保存也具有较大的影响,体外培养4d和8d的微囊化细胞在液氮中冷冻保存40d,复苏后细胞生长良好、内皮抑素表达量高,而冻存前未经过体外培养的微囊化细胞,复苏后细胞几乎全部死亡。综上所述,生物微胶囊在体外比较适宜的培养时间为4d。并且冷冻保存对微囊化细胞在动物体内生长、内皮抑素表达和微囊稳定性没有显著的影响。     

表达内皮抑素的rCHO细胞的微囊化培养

微囊化重组基因细胞移植治疗肿瘤是一种新兴的肿瘤基因治疗方法,如果将此技术应用到临床研究,就需要制备大量的细胞活性良好、重组蛋白表达量高的生物微胶囊。种子细胞是生物微胶囊治疗作用的执行者, 是构建微囊微反应器的基本元素。如何获得大量高活性的种子细胞已经成为规模化制备生物微胶囊所面临的最关键的限制因素。本实验考察了搅拌式生物反应器内扩增的重组CHO细胞进行包囊及微囊化细胞在生物反应器内规模化培养的可行性。实验结果显示:重组CHO细胞在生物反应器内可以快速生长,并且对数期细胞包囊,微囊化细胞活性良好。制备的微囊化细胞可以在生物反应器内培养,与培养板培养比较细胞生长较快、内皮抑素表达量较高。应用生物反应器培养技术能够在体外快速、大量扩增重组CHO细胞,满足微囊化细胞制备对种子细胞量与质的要求,微囊化细胞可以在生物反应器内培养。     

谷氨酰胺对微囊化重组CHO细胞生长代谢及内皮抑素表达的影响

微囊化技术是一种有发展潜力的生物技术,在细胞移植和药物控释等方面具有广泛的应用。然而由于目前微囊化细胞规模化培养技术还不成熟,阻碍了其在临床治疗中的推广与应用。为了了解微囊化重组CHO细胞的生长代谢特性为今后规模化培养优化提供技术参考,考察了主要氮源物质谷氨酰胺对微囊化重组CHO细胞生长代谢及内皮抑素表达的影响。结果显示:当谷氨酰胺起始浓度从2.69mmolL增加到9.05mmolL时最大活细胞密度并没有增高,细胞增殖没有显著差异。当谷氨酰胺起始浓度较低(2.69mmolL)时,葡萄糖的比消耗速率较大;当谷氨酰胺起始浓度增高时(7.91mmolL～9.05mmolL)葡萄糖和谷氨酰胺的比消耗速率增大,但细胞对葡萄糖和谷氨酰胺的利用率降低。谷氨酰胺对产物表达有显著影响,起始浓度为4.97mmolL时的内皮抑素累积浓度最高,达546.36ngmL,过低和过高谷氨酰胺起始浓度下内皮抑素的累积浓度均较低。     

用昆虫细胞表达系统表达人组织激肽释放酶原

目的:利用杆状病毒-昆虫细胞表达系统表达proHUK,系统优化表达条件。方法:用改进的方法对昆虫细胞进行了无血清悬浮适应培养,用ELISA、SDS-PAGE方法对各种条件下proHUK的表达量进行检测。结果:Sf-9、Hi-5细胞在血清减量速度为5%、1%,接种密度分别为2×106cells/mL1、×106cells/mL时能很快适应无血清悬浮培养。在病毒感染复度MOI为10,细胞接种密度为1×106cells/mL条件下培养96h后,proHUK的表达量最高可达30mg/L。结论:改进的方法使昆虫细胞能更快适应无血清悬浮生长条件,获得了高表达proHUK的方法,为其大规模制备奠定了基础。     

鼠源休眠蛋白具有抑制内皮细胞增殖和诱导细胞凋亡的活性

内皮抑素 (endostatin)是最近发现的一种具有抑制血管生长的蛋白质。休眠蛋白 (restin)是内皮抑素的同源蛋白质 ,最早由Ramchandran等人发现 ,它来源于胶原蛋白XV的羧端非胶原蛋白结构域 (NC1)。为了研究鼠源休眠蛋白对内皮细胞生长的影响 ,利用RT PCR从鼠肌肉中扩增出它的基因 ,克隆入原核表达载体pQE32。诱导后 ,重组蛋白质以包涵体形式高效表达 ,表达量约占菌体总蛋白质的 6 0 %～ 70 %。重组蛋白质经纯化复性后 ,可以特异地抑制bFGF刺激的牛主动脉内皮细胞的增殖 ,但是休眠蛋白的抑制活性比内皮抑素活性稍低。流式细胞仪检测发现 ,休眠蛋白可以引起内皮细胞的细胞周期的改变 ,并且引起细胞凋亡     

腺相关病毒载体介导的人内皮抑素的体外表达及对内皮细胞抑制作用的研究

抗血管生成基因治疗是一有希望的抑制肿瘤生长及转移的方法.在实验中构建了含有人内皮抑素(endostatin)基因的重组腺相关病毒载体rAAV-hE.所包装纯化的重组病毒滴度达0.5×1012v.g./ml.rAAV-hE能有效感染培养细胞,EIA法检测培养液上清中内皮抑素浓度达36.42ng/ml.rAAV介导所表达的内皮抑素对人脐静脉内皮细胞(ECV-304)和牛毛细血管内皮细胞(BCE)具有抗增殖抑制作用,抑制率分别为68.1%和41.6%.此结果为进一步的动物实验奠定了基础,表明重组腺相关病毒载体介导的抗血管生成有望应用于肿瘤基因治疗.     

内皮抑素30肽基因真核表达载体的构建及实验研究

目的构建改构内皮抑素抗肿瘤相关肽（30肽）的真核表达载体pVAX1,检测该重组载体的生物学活性。方法在30肽基因的5′端加入胶原蛋白ⅩⅧ信号肽编码序列,通过PCR扩增获得目的基因30肽,并连接到质粒pVAX1中,构建表达分泌型内皮抑素的重组质粒pVAX1-30E,然后将重组质粒pVAX1-30E直接注入小鼠肿瘤组织。通过ELISA小鼠体内抑瘤实验检测目的基因的表达及其活性。结果ELISA实验表明构建的分泌型内皮抑素重组质粒pVAX1-30E能在肿瘤细胞中表达30肽,免疫组化结果表明瘤组织中表达的30肽能抑制肿瘤微血管的新生,而体内抑瘤实验表明在肿瘤部位直接注射重组质粒能抑制肿瘤生长,抑瘤率为28.19%。结论通过向瘤组织中直接注射分泌型内皮抑素重组质粒pVAX1-30E可以抑制小鼠体内肿瘤微血管新生和肿瘤生长而实现其抗肿瘤活性。     

微囊化K562细胞生长周期及代谢特性的研究

以K562细胞为模型,分别进行微囊化和游离培养,运用流式细胞术考察两种培养体系下细胞周期和生长代谢变化;建立数学模型,模拟了两种培养体系下细胞的生长活性和代谢特性。实验发现：微囊化培养过程中的K562细胞处于DNA合成期（S期）的百分含量显著高于游离培养,并且细胞保持较高的增殖活性。模型计算表明,所建模型动力学参数能够很好地描述微囊化和游离两种培养体系下细胞的代谢情况;对细胞活性的理论计算表明,微囊化的细胞具有较高的增殖和代谢活性,同时细胞能够较长时间保持此活性;模型参数表明,两种培养体系下,葡萄糖对细胞生长的影响无显著差别 (k^Free_L≈k^APA_L),乳酸对游离培养细胞的生长具有明显抑制作用,但对微囊化培养细胞抑制作用较小(kFreeL>≈kAPAL)。     

粒径对微胶囊成膜及微囊化细胞生长代谢的影响

目的:考察粒径对微胶囊强度及微囊化细胞生长代谢的影响,为制备性能优良的生物微胶囊提供实验依据。方法:制备不同粒径的凝胶珠,测定其在相同成膜条件下的球磨强度,进而用台盘蓝拒染法测定微囊化细胞的增殖及活率。结果:小粒径的微胶囊具有更厚的微囊膜及更高的球磨强度,另外小粒径微胶囊培养细胞能够获得更多的细胞数(350μm,570μm和900μm微囊内的细胞数量分别为:5.67×107、4.71×107和3.89×107/mL microcapsule,P<0.05)及更高的细胞活率(350μm、570μm和900μm微胶囊的细胞活率分别为:83.70%、67.64%和75.73%,P<0.05)。结论:粒径能影响微胶囊的强度及微囊化细胞的生长、代谢。     

人血管抑素（k1—3）在家蚕细胞和幼虫中的表达及活性测定

将人血管抑素 (angiostatin)基因重组于家蚕杆状病毒转移载体 pBacPAK8中 ,获得重组转移载体pBacPAK angiostatin ,并与被线性化的Bm BacPAK6病毒DNA共转染家蚕细胞 ,获得重组病毒BacPAK angiostatin。DNA点杂交结果表明重组病毒基因组中含有血管抑素基因。重组病毒以MOI=10感染家蚕细胞 (2×10 6个细胞 /瓶 )和家蚕 5龄幼虫 ,表达产物用体外培养的人脐静脉血管内皮细胞 (ECV30 4 )及体内鸡胚尿囊膜(CAM)新生血管实验检测其抑制活性 ,测得血管抑素可明显抑制体外培养的内皮细胞增殖 ,家蚕细胞的产物活性在表达 72h达到最高值 ,在 2× 10 6个细胞中的表达量约 2 2u ;在家蚕体内表达 14 4h生物活性达到最高值 ,表达量约 15 9u/ml。2 .5u/ml的血管抑素能使ECV30 4细胞在 2 4h发生明显凋亡 ;可使CAM新生血管化率明显下降。此外 ,用ELISA、Western印迹方法测定了表达产物的免疫反应性。     

Optimization of the cell seeding density and modeling of cell growth and metabolism using the modified Gompertz model for microencapsulated animal cell culture

Cell microencapsulation is one of the promising strategies for the in vitro production of proteins or in vivo delivery of therapeutic products. In order to design and fabricate the optimized microencapsulated cell system, the Gompertz model was applied and modified to describe the growth and metabolism of microencapsulated cell, including substrate consumption and product formation. The Gompertz model successfully described the cell growth kinetics and the modified Gompertz models fitted the substrate consumption and product formation well. It was demonstrated that the optimal initial cell seeding density was about 4-5 x 10(6) cells/mL of microcapsule, in terms of the maximum specific growth rate, the glucose consumption potential and the product formation potential calculated by the Gompertz and modified Gompertz models. Modeling of cell growth and metabolism in microcapsules provides a guideline for optimizing the culture of microencapsulated cells.     

Serum- and protein-free media formulations for the Chinese hamster ovary cell line DUKXB11

The production of therapeutic proteins in mammalian cell lines is of outstanding importance. The maintenance of most mammalian cell lines in culture requires the addition of serum to the culture medium. The elimination of serum from mammalian cell culture is desirable since serum is expensive and a source of contaminants, e.g. viruses, mycoplasma or prions. Here we describe the composition of serum- and protein-free media for the Chinese hamster ovary (CHO) cell line DUKXB11. The serum-free formulation supports excellent growth of CHO DUKXB11 cells at low (23cells/cm2) and high (2 x 10(4) cells/cm2) seeding densities characterized by a generation time of 10-12h, and, after addition of 0.2% pluronic F-68, the growth of a recombinant suspension cell line derived from DUKXB11. In addition, this formulation also allowed us to adapt recombinant cell lines expressing various amounts of human antithrombin ATIII (ATIII) to serum-free conditions. Secretion of ATIII was readily observed in the serum-free medium. Minor changes to the serum-free formulation resulted in a protein free formulation that supported growth of CHO DUKXB11 cells, growth of recombinant CHO cells expressing ATIII, and production of ATIII.     

Inhibition of tumor growth in mice by endostatin derived from abdominal transplanted encapsulated cells

Endostatin,a C-terminal fragment of collagen 18a,inhibits the growth of established tumorsand metastases in vivo by inhibiting angiogenesis.However,the purification procedures required for large-scale production and the attendant cost of these processes,together with the low effectiveness in clinicaltests,suggest that alternative delivery methods might be required for efficient therapeutic use of endostatin.In the present study,we transfected Chinese hamster ovary(CHO)cells with a human endostatin geneexpression vector and encapsulated the CHO cells in alginate-poly-L-lysine microcapsules.The release ofbiologically active endostatin was confirmed using the chicken chorioallantoic membrane assay.The encap-sulated endostatin-expressing CHO cells can inhibit the growth of primary tumors in a subcutaneous B 16tumor model when injected into the abdominal cavity of mouse.These results widen the clinical applicationof the microencapsulated cell endostatin delivery system in cancer treatment.     

Growth of recombinant fibroblasts in alginate microcapsules

To develop a novel strategy of nonautologous somatic gene therapy, we now demonstrate the feasibility of culturing genetically modified fibroblasts within an immunoprotective environment and the optimal conditions required for their continued survival in vitro. When mouse Ltk(-) fibroblasts transfected with the human growth hormone gene were enclosed within permselective microcapsules fabricated from alginate-polylysine-alginate, they continued to secrete human growth hormone at the same rates as the nonencapsulated cells. They also continued to proliferate in vitro for at least 1 month even though their viability gradually declined to about 50%. The viability can be improved by controlling for (a) temperature during encapsulation, (b) duration of treatment with polylysine, (c) duration of liquefying the core alginate with sodium citrate, and (d) cell density at the time of encapsulation. The best conditions leading to improved survival and maximum proliferation of cells within the microcapsules were obtained by encapsulating the cells at 4 to 10 degrees C instead of room temperature, coating the microspheres with polylysine for 6 to 10 min instead of 20 min, liquefying the core alginate by treating with citrate for 20 min instead of 6 to 10 min, and using a concentration of 2 x 10(6) cells/mL of alginate for encapsulation. Under such conditions, normally adherent and genetically engineered mouse fibroblasts survived and proliferated optimally within the microcapsule environment. The encapsulated fibroblasts maintained their level of transgene expression while recombinant gene products such as human growth hormone could diffuse through the microcapsule membrane without impediment. The demonstration that genetically modified fibroblasts can survive and continue to deliver recombinant gene products from within these microcapsules and the optimization for their maximal viability and growth within microcapsules should increase the potential for success in using such microencapsulated recombinant cells for somatic gene therapy. (c) 1994 John Wiley & Sons, Inc.     

High-level expression and secretion of recombinant mouse endostatin by Escherichia coli

The expression of murine endostatin was achieved by placing its gene downstream of an alkaline phosphatase gene (phoA) promoter. To ensure proper folding and secretion of the recombinant protein, the mouse endostatin was fused with alkaline phosphatase signal peptide. SDS/polyacrylamide gel electrophoresis analysis of the culture medium of recombinant Escherichia coli cells revealed that endostatin was efficiently secreted. The signal peptide was efficiently cleaved during secretion as demonstrated by N-terminal amino acid sequencing. The maximum yield of secreted endostatin during fermentation was 40 mg/liter. Up to 28 mg of endostatin was purified from 1 liter of cell culture broth. The biological activity of recombinant protein was tested in a bovine aortic endothelial (BAE) cell proliferation assay. The recombinant endostatin inhibited the growth of BAE cells stimulated by basic fibroblast growth factor, and its ED50 was comparable to that from a previous report. Flow cytometric measurements of BAE cells cultivated in medium with endostatin demonstrated a cell cycle arrest mainly in the G0/G1 phase and a decrease in the S phase.     

中国仓鼠卵巢工程细胞无血清流加培养关键工艺参数的考察

主要考察流加培养基中不同营养成分、流加起始时间及初始接种密度对11G-S细胞无血清流加培养的影响。在研究中以悬浮适应的表达尿激酶原 (Pro-urokinase,Pro-UK) CHO工程细胞系11G-S为研究对象,在100 mL的摇瓶中无血清悬浮流加培养11G-S细胞,同时以活细胞密度、细胞活力及Pro-UK活性为评价依据。结果表明在培养基中氨基酸、无血清添加成分及无机盐对促进细胞生长、细胞活力维持及蛋白表达起着较为重要的作用;且流加起始时间为72 h及初始接种密度为3×105~4×105 cells/